CN104116990A - Medicinal composition for treating diabetes mellitus and preparation method thereof - Google Patents
Medicinal composition for treating diabetes mellitus and preparation method thereof Download PDFInfo
- Publication number
- CN104116990A CN104116990A CN201410363268.1A CN201410363268A CN104116990A CN 104116990 A CN104116990 A CN 104116990A CN 201410363268 A CN201410363268 A CN 201410363268A CN 104116990 A CN104116990 A CN 104116990A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- fructus
- pharmaceutical composition
- ginseng rubra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention aims to disclose a medicinal composition for treating diabetes mellitus, and a preparation method of the composition. The medicinal composition is prepared from the following raw medicinal materials in parts by weight: 120-220 parts of radix ophiopogonis, 80-180 parts of guava leaf, 30-150 parts of red ginseng, 30-180 parts of alpinia oxyphylla, 50-160 parts of Chinese yam, 50-180 parts of rhizoma atractylodis macrocephalae, 30-180 parts of hawthorn, 30-160 parts of raw rehmannia, 30-120 parts of cortex lycii radicis, 30-120 parts of kudzu vine root, 30-120 parts of Lilium brownii, 20-120 parts of schisandra chinensis, 30-120 parts of fructus lycii and 30-150 parts of glycyrrhiza uralensis. Conventional auxiliary materials can be added into the medicinal composition to prepare clinically acceptable tablets, granules, pills, capsules, oral liquid preparations and the like according to a conventional process.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and preparation method thereof, specifically, relate to a kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof.
Background technology
Diabetes are by inherited genetic factors, immunologic function disorder, infected by microbes and toxin thereof, free radical toxin, the various virulence factors of Nervous and Mental Factors etc. act on body and cause hypoinsulinism, insulin resistant etc. and cause sugar, protein, fat, a series of metabolism disorder syndromes such as power and water Xie Zhi, clinically taking hyperglycemia as main feature, can there is polyuria in model case, polydipsia, polyphagia, the performance such as become thin, i.e. " three-many-one-little " symptom, diabetes (blood glucose) cause diabetic complication once control bad meeting, cause kidney, eye, the exhaustion pathological changes at the positions such as foot, and cannot cure.
Diabetes are because people's islet function is impaired, and the insulin secretion causing is definitely or relative deficiency, and the sugar causing, protein, and the metabolism disorder of fat, cardinal symptom is three-many-one-little, and that eats is many, and that drinks is many, and urine lose weight more.
Diabetes can cause multiple complications.If diabetes do not obtain enough control, can cause some acute complicationses, as hypoglycemia, ketoacidosis, non-ketone hyperosmolar coma.Serious long-term complications comprises: cardiovascular disease, chronic renal failure (claim again diabetic nephropathy, the main cause of hemodialysis in the adult of developing country), retinopathy (claims again diabetic ophthalmopathy, can blinding, be the principal disease of the non-aged adult's blinding of developing country), neuropathy and microangiopathies.Wherein, microangiopathies may cause erection disturbance (sexual impotence) and wound to be difficult to healing.The wound that foot is difficult to healing may cause gangrene (being commonly called as " diabetic foot "), and then causes patient's amputation.If diabetes have obtained enough control, and blood pressure is fully controlled and in conjunction with good living habit (as non-smoking, the body weight of keeping fit etc.), can effectively reduced the danger of suffering from above-mentioned complication.
World Health Organization (WHO) 2011 report point out that the whole world has 3.46 hundred million people to suffer from diabetes, within 2004, estimate at 3,400,000 people and die from the consequence that hyperglycemia causes, exceed 80% Diabetes Death and occur in low income and middle income country.
Doctor trained in Western medicine does not have applicable Therapeutic Method for the treatment of diabetes, cannot effect a radical cure.Motherland's medical science extensive knowledge and profound scholarship, by prescription compatibility, having certain advantage and curative effect, but the blood sugar lowering of Chinese patent medicine takes effect slowly at present, poor effect aspect treatment diabetes.
Summary of the invention
The object of the invention is to openly a kind of pharmaceutical composition for the treatment of diabetes, the present invention also aims to the preparation method of open said composition.
A kind of pharmaceutical composition for the treatment of diabetes involved in the present invention, it is mainly by crude drug Radix Ophiopogonis, Folium Psidii Guajavae, the Rhizoma Atractylodis Macrocephalae, Radix Ginseng Rubra, Radix Rehmanniae, Radix Puerariae, Cortex Lycii, Fructus Crataegi, the Radix Paeoniae Alba, Bulbus Lilii, Fructus Lycii, Rhizoma Dioscoreae, Fructus Alpiniae Oxyphyllae, Fructus Schisandrae Chinensis, Radix Glycyrrhizae is made.
The card that formula of the present invention cures mainly is by due to hyperactivity of fire caused by deficiency of YIN, monarch drug YIN nourishing and the production of body fluid promoting Radix Ophiopogonis, ministerial drug Folium Psidii Guajavae heat-clearing and toxic substances removing, Radix Ginseng Rubra QI invigorating, the warm spleen of Fructus Alpiniae Oxyphyllae the kidney warming, Rhizoma Dioscoreae, the Rhizoma Atractylodis Macrocephalae and Fructus Crataegi spleen reinforcing stomach reinforcing, be adjuvant drug altogether, and the Radix Rehmanniae, Cortex Lycii, Radix Puerariae and Bulbus Lilii relieving restlessness are quenched the thirst, Fructus Schisandrae Chinensis, Fructus Lycii, Radix Paeoniae Alba tonifying liver kidney yin, for making medicine, the full side of Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription share, and plays altogether Yin-nourishing and body fluid promoting altogether, clearing heat and relieving fidgetness, effect of strengthening spleen, tonifying kidney.
The present invention is for the diabetics of clinical common type of hyperactivity of fire caused by deficiency of YIN, and disease is seen dysphoria with feverish sensation in the chest palms and soles, being irritable and getting angry easily, and xerostomia is thirsty, thirst and desire for cold drink, the sweating constantly of easy hungry polyphagia, little sleep disturbed by dreams, the red constipation of urinating, the red few tongue of red tongue, deficient pulse stringy and rapid pulse.
The consumption of Chinese medicine composition of the present invention and drug component thereof is also groped in a large number to sum up through inventor and is drawn.
Composition and the weight portion of a kind of pharmaceutical composition for the treatment of diabetes of described treatment are: Radix Ophiopogonis 120-220 part, Folium Psidii Guajavae 80-180 part, Radix Ginseng Rubra 30-150 part, Fructus Alpiniae Oxyphyllae 30-180 part, Rhizoma Dioscoreae 50-160 part, Rhizoma Atractylodis Macrocephalae 50-180 part, Fructus Crataegi 30-180 part, Radix Rehmanniae 30-160 part, Cortex Lycii 30-120 part, Radix Puerariae 30-120 part, Bulbus Lilii 30-120 part, Fructus Schisandrae Chinensis 20-120 part, Fructus Lycii 30-120 part, Radix Glycyrrhizae 30-150 part.
Further composition and the weight portion of a kind of pharmaceutical composition for the treatment of diabetes of described treatment are: Radix Ophiopogonis 140-200 part, Folium Psidii Guajavae 100-160 part, Radix Ginseng Rubra 50-120 part, Fructus Alpiniae Oxyphyllae 50-160 part, Rhizoma Dioscoreae 60-130 part, Rhizoma Atractylodis Macrocephalae 60-150 part, Fructus Crataegi 40-150 part, Radix Rehmanniae 40-140 part, Cortex Lycii 40-100 part, Radix Puerariae 40-100 part, Bulbus Lilii 40-100 part, Fructus Schisandrae Chinensis 30-100 part, Fructus Lycii 40-100 part, Radix Glycyrrhizae 40-120 part.
Preferred composition and the weight portion of a kind of pharmaceutical composition for the treatment of diabetes of described treatment are: 200 parts of Radix Ophiopogonis, 120 parts of Folium Psidii Guajavae, 50 parts of Radix Ginseng Rubra, 50 parts of Fructus Alpiniae Oxyphyllae, 90 parts of Rhizoma Dioscoreaes, 100 parts of the Rhizoma Atractylodis Macrocephalaes, 90 parts of Fructus Crataegis, 80 parts of Radix Rehmanniae, 60 parts of Cortex Lycii, 60 parts of Radix Puerariaes, 50 parts of Bulbus Liliies, 30 parts of Fructus Schisandrae Chinensis, 40 parts of Fructus Lycii, 90 parts, Radix Glycyrrhizae.
Preferred composition and the weight portion of a kind of pharmaceutical composition for the treatment of diabetes of described treatment are: 160 parts of Radix Ophiopogonis, 100 parts of Folium Psidii Guajavae, 60 parts of Radix Ginseng Rubra, 50 parts of Fructus Alpiniae Oxyphyllae, 80 parts of Rhizoma Dioscoreaes, 120 parts of the Rhizoma Atractylodis Macrocephalaes, 100 parts of Fructus Crataegis, 110 parts of Radix Rehmanniae, 60 parts of Cortex Lycii, 70 parts of Radix Puerariaes, 80 parts of Bulbus Liliies, 65 parts of Fructus Schisandrae Chinensis, 55 parts of Fructus Lycii, 60 parts, Radix Glycyrrhizae.
Preferred composition and the weight portion of a kind of pharmaceutical composition for the treatment of diabetes of described treatment are: 180 parts of Radix Ophiopogonis, 130 parts of Folium Psidii Guajavae, 60 parts of Radix Ginseng Rubra, 65 parts of Fructus Alpiniae Oxyphyllae, 80 parts of Rhizoma Dioscoreaes, 120 parts of the Rhizoma Atractylodis Macrocephalaes, 110 parts of Fructus Crataegis, 90 parts of Radix Rehmanniae, 80 parts of Cortex Lycii, 70 parts of Radix Puerariaes, 75 parts of Bulbus Liliies, 85 parts of Fructus Schisandrae Chinensis, 80 parts of Fructus Lycii, 120 parts, Radix Glycyrrhizae.
In a word, the present invention forms monarch, minister, it is various to help, make, and compatibility is rigorous, complements each other, and plays altogether Yin-nourishing and body fluid promoting clearly, clearing heat and relieving fidgetness, effect of strengthening spleen, tonifying kidney.
Medicine of the present invention can add conventional adjuvant, according to common process, makes clinical acceptable tablet, granule, pill, capsule, oral liquid etc.
The tablet of the preparation of medicine of the present invention or the method for capsule comprise the steps:
Radix Ginseng Rubra, Rhizoma Dioscoreae, above three tastes of Radix Puerariae are ground into fine powder, sieve.All the other ten decoctings simply, concentrated, dry.The two mixes, and granule processed is dry, encapsulated or tabletting.
The preparation method of the pill of medicine of the present invention comprises the steps: Radix Ginseng Rubra, Rhizoma Dioscoreae, and above three tastes of Radix Puerariae are ground into fine powder, sieve.All the other ten decoctings simply, concentrated, close medicated powder and mix general mould, make the watered pill.
The preparation method of the oral liquid of medicine of the present invention comprises the steps: after above 13 taste decoctings, concentrates, and Radix Ginseng Rubra list is decocted, and the two mixes, and filters, and makes oral liquid.
The preparation method of medicine of the present invention preferably includes following steps: Radix Codonopsis, and Rhizoma Dioscoreae, above three tastes of Poria are ground into fine powder, sieve.All the other ten decoctings 2 times simply, each 30 minutes, concentrated, spraying was dry.Mix, granule processed, dry, make capsule or tablet.
Detailed description of the invention
Following examples are used for illustrating the present invention, but are not used for limiting the scope of the invention.
Embodiment 1
1, prescription:
Radix Ophiopogonis 200g, Folium Psidii Guajavae 120g, Radix Ginseng Rubra 50g, Fructus Alpiniae Oxyphyllae 50g, Rhizoma Dioscoreae 90g, Rhizoma Atractylodis Macrocephalae 100g, Fructus Crataegi 90g, Radix Rehmanniae 80g, Cortex Lycii 60g, Radix Puerariae 60g, Bulbus Lilii 50g, Fructus Schisandrae Chinensis 30g, Fructus Lycii 40g, Radix Glycyrrhizae 90g.
2. method for making:
Radix Ginseng Rubra, Rhizoma Dioscoreae, above three tastes of Radix Puerariae are ground into fine powder, sieve.All the other ten decoctings simply, concentrated, dry.The two mixes, and granule processed is dry, makes tablet, makes 2000, to obtain final product.
Embodiment 2
1, prescription:
Radix Ophiopogonis 160g, Folium Psidii Guajavae 100g, Radix Ginseng Rubra 60g, Fructus Alpiniae Oxyphyllae 50g, Rhizoma Dioscoreae 80g, Rhizoma Atractylodis Macrocephalae 120g, Fructus Crataegi 100g, Radix Rehmanniae 110g, Cortex Lycii 60g, Radix Puerariae 70g, Bulbus Lilii 80g, Fructus Schisandrae Chinensis 65g, Fructus Lycii 55g, Radix Glycyrrhizae 60g.
2. method for making:
Radix Ginseng Rubra, Rhizoma Dioscoreae, above three tastes of Radix Puerariae are ground into fine powder, sieve.All the other ten decoctings simply, concentrated, close medicated powder and mix general mould, make the watered pill, to obtain final product.
Embodiment 3
1, prescription:
Radix Ophiopogonis 180g, Folium Psidii Guajavae 130g, Radix Ginseng Rubra 60g, Fructus Alpiniae Oxyphyllae 65g, Rhizoma Dioscoreae 80g, Rhizoma Atractylodis Macrocephalae 120g, Fructus Crataegi 110g, Radix Rehmanniae 90g, Cortex Lycii 80g, Radix Puerariae 70g, Bulbus Lilii 75g, Fructus Schisandrae Chinensis 85g, Fructus Lycii 80g, Radix Glycyrrhizae 120g.
2, technique:
Radix Codonopsis, Rhizoma Dioscoreae, above three tastes of Poria are ground into fine powder, sieve.All the other ten decoctings 2 times simply, each 30 minutes, concentrated, spraying was dry.Mix, granule processed, dry, make capsule, make 2000, to obtain final product.
Embodiment 4
1, prescription:
Radix Ophiopogonis 160g, Folium Psidii Guajavae 100g, Radix Ginseng Rubra 60g, Fructus Alpiniae Oxyphyllae 50g, Rhizoma Dioscoreae 80g, Rhizoma Atractylodis Macrocephalae 120g, Fructus Crataegi 100g, Radix Rehmanniae 110g, Cortex Lycii 60g, Radix Puerariae 70g, Bulbus Lilii 80g, Fructus Schisandrae Chinensis 65g, Fructus Lycii 55g, Radix Glycyrrhizae 60g.
2. method for making:
After above 13 taste decoctings, concentrated, Radix Ginseng Rubra list is decocted, and the two mixes, and filters, and makes oral liquid 3000ml, to obtain final product.
Embodiment 5
1, prescription:
Radix Ophiopogonis 180g, Folium Psidii Guajavae 130g, Radix Ginseng Rubra 60g, Fructus Alpiniae Oxyphyllae 65g, Rhizoma Dioscoreae 80g, Rhizoma Atractylodis Macrocephalae 120g, Fructus Crataegi 110g, Radix Rehmanniae 90g, Cortex Lycii 80g, Radix Puerariae 70g, Bulbus Lilii 75g, Fructus Schisandrae Chinensis 85g, Fructus Lycii 80g, 120 parts, Radix Glycyrrhizae.
2. method for making:
Radix Codonopsis, Rhizoma Dioscoreae, above three tastes of Poria are ground into fine powder, sieve.All the other ten decoctings 2 times simply, each 30 minutes, concentrated, spraying was dry.Mix, granule processed, dry, make 2000, tablet, to obtain final product.
Embodiment 6 tests of pesticide effectiveness: flat sugar-tablet causes the impact of hyperglycemia mice on alloxan
[test material]
Tested medicine: flat sugar-tablet: sepia, 0.35g/ sheet, is made by embodiment 1, with the front suspension that is made into required concentration with distilled water.
Glibenclamide tablet: Tianjin Lik-Sang pharmaceutical factory product batch number, lot number 20100302.
[test method and result]
Get 50 healthy mices, male and female half and half, body weight 20-22 gram, leaves 10, and all the other mice fasting are equal lumbar injection alloxan 250mg/kg after 16 hours, drinks 10% glucose solution in 24 hours, after 3 days, surveys blood glucose.Be divided at random 8 groups according to blood glucose value, male and female half and half, administration group and glyburide group are pressed respectively the dosed administration in table, model group: give consubstantiality hydrops, continuously gavage 5 days, after last administration, fasting 10 hours, broken end is got blood, conventional separation of serum, press blood sugar detection test kit with determination of glucose oxidase mouse's blood sugar content, the results are shown in Table 1.
The impact (n=10) of the flat sugar-tablet of table 1 on Alloxan-diabetes mouse blood sugar
Note: each administration group and model control group comparison, * P < 0.05; * P < 0.01
Model control group and the comparison of blank group, Δ Δ P < 0.01.
As shown in Table 1, model control group and the comparison of blank group, P < 0.01, illustrates model success.Flat sugar-tablet high and low dose group all can alleviate the blood glucose of Alloxan-diabetes mice, and statistical result has remarkable statistical significance.
The impact of the flat sugar-tablet of embodiment 7 on epinephrine type blood glucose in diabetic mice
[test material]
Tested medicine: flat sugar-tablet: sepia, 0.35g/ sheet, is made by embodiment 1, with the front suspension that is made into required concentration with distilled water.
Glibenclamide tablet: Tianjin Lik-Sang pharmaceutical factory product batch number, lot number 20100302.
[test method and result]
Get 50 healthy mices, male and female half and half, body weight 20-22 gram, is divided into 5 groups at random, blank group is normally raised, model group gives same volume distilled water, and each administration group and positive group are by the gastric infusion respectively of dosage in table, every day 1 time, 5d continuously, 2h after last administration, except normal group ip normal saline, all the other respectively organize the equal ip epinephrine inj of mice.0.2mg/kg, after injection, 30min respectively organizes mice broken end and gets blood.Each administration group blood glucose value and model group are relatively carried out t inspection, the results are shown in Table 2.
The results are shown in Table 2: the impact (n=10) of flat sugar-tablet on epinephrine type blood glucose in diabetic mice
Each administration group and model control group comparison, * P < 0.05; * P < 0.01
Model control group and the comparison of blank group, Δ Δ P < 0.01.
As shown in Table 2, model control group and the comparison of blank group, P < 0.01, illustrates model success.Flat sugar-tablet high and low dose group all can alleviate the blood glucose of epinephrine type diabetic mice, and statistical result has remarkable statistical significance.
Claims (10)
1. treat a pharmaceutical composition for diabetes, it is characterized in that the composition of the crude drug of making this medicine and weight portion are: Radix Ophiopogonis 120-220 part, Folium Psidii Guajavae 80-180 part, Radix Ginseng Rubra 30-150 part, Fructus Alpiniae Oxyphyllae 30-180 part, Rhizoma Dioscoreae 50-160 part, Rhizoma Atractylodis Macrocephalae 50-180 part, Fructus Crataegi 30-180 part, Radix Rehmanniae 30-160 part, Cortex Lycii 30-120 part, Radix Puerariae 30-120 part, Bulbus Lilii 30-120 part, Fructus Schisandrae Chinensis 20-120 part, Fructus Lycii 30-120 part, Radix Glycyrrhizae 30-150 part.
2. a kind of pharmaceutical composition for the treatment of diabetes according to claim 1, is characterized in that the composition of the crude drug of making this medicine and weight portion are: Radix Ophiopogonis 140-200 part, Folium Psidii Guajavae 100-160 part, Radix Ginseng Rubra 50-120 part, Fructus Alpiniae Oxyphyllae 50-160 part, Rhizoma Dioscoreae 60-130 part, Rhizoma Atractylodis Macrocephalae 60-150 part, Fructus Crataegi 40-150 part, Radix Rehmanniae 40-140 part, Cortex Lycii 40-100 part, Radix Puerariae 40-100 part, Bulbus Lilii 40-100 part, Fructus Schisandrae Chinensis 30-100 part, Fructus Lycii 40-100 part, Radix Glycyrrhizae 40-120 part.
3. a kind of pharmaceutical composition for the treatment of diabetes according to claim 2, is characterized in that the composition of the crude drug of making this medicine and weight portion are: 200 parts of Radix Ophiopogonis, 120 parts of Folium Psidii Guajavae, 50 parts of Radix Ginseng Rubra, 50 parts of Fructus Alpiniae Oxyphyllae, 90 parts of Rhizoma Dioscoreaes, 100 parts of the Rhizoma Atractylodis Macrocephalaes, 90 parts of Fructus Crataegis, 80 parts of Radix Rehmanniae, 60 parts of Cortex Lycii, 60 parts of Radix Puerariaes, 50 parts of Bulbus Liliies, 30 parts of Fructus Schisandrae Chinensis, 40 parts of Fructus Lycii, 90 parts, Radix Glycyrrhizae.
4. a kind of pharmaceutical composition for the treatment of diabetes according to claim 2, is characterized in that the composition of the crude drug of making this medicine and weight portion are: 160 parts of Radix Ophiopogonis, 100 parts of Folium Psidii Guajavae, 60 parts of Radix Ginseng Rubra, 50 parts of Fructus Alpiniae Oxyphyllae, 80 parts of Rhizoma Dioscoreaes, 120 parts of the Rhizoma Atractylodis Macrocephalaes, 100 parts of Fructus Crataegis, 110 parts of Radix Rehmanniae, 60 parts of Cortex Lycii, 70 parts of Radix Puerariaes, 80 parts of Bulbus Liliies, 65 parts of Fructus Schisandrae Chinensis, 55 parts of Fructus Lycii, 60 parts, Radix Glycyrrhizae.
5. a kind of pharmaceutical composition for the treatment of diabetes according to claim 2, is characterized in that the composition of the crude drug of making this medicine and weight portion are: 180 parts of Radix Ophiopogonis, 130 parts of Folium Psidii Guajavae, 60 parts of Radix Ginseng Rubra, 65 parts of Fructus Alpiniae Oxyphyllae, 80 parts of Rhizoma Dioscoreaes, 120 parts of the Rhizoma Atractylodis Macrocephalaes, 110 parts of Fructus Crataegis, 90 parts of Radix Rehmanniae, 80 parts of Cortex Lycii, 70 parts of Radix Puerariaes, 75 parts of Bulbus Liliies, 85 parts of Fructus Schisandrae Chinensis, 80 parts of Fructus Lycii, 120 parts, Radix Glycyrrhizae.
6. the pharmaceutical composition as described in as arbitrary in claim 1-5, is characterized in that getting crude drug, adds conventional adjuvant, according to common process, makes clinical acceptable tablet, granule, pill, capsule, oral liquid.
7. the preparation method of the pharmaceutical composition as described in as arbitrary in claim 1-5, comprises the steps: Radix Ginseng Rubra, Rhizoma Dioscoreae, and above three tastes of Radix Puerariae are ground into fine powder, sieve, all the other ten decoctings simply, concentrated, dry.The two mixes, and granule processed is dry, encapsulated or tabletting.
8. the preparation method of the pharmaceutical composition as described in as arbitrary in claim 1-5, comprises the steps: Radix Ginseng Rubra, Rhizoma Dioscoreae, and above three tastes of Radix Puerariae are ground into fine powder, sieve, all the other ten decoctings simply, concentrated, close medicated powder and mix general mould, make the watered pill.
9. the preparation method of the pharmaceutical composition as described in as arbitrary in claim 1-5, comprises the steps: after above 13 taste decoctings, and concentrated, Radix Ginseng Rubra list is decocted, and the two mixes, and filters, and makes oral liquid.
10. the preparation method of pharmaceutical composition as claimed in claim 7, comprises the steps: Radix Codonopsis, Rhizoma Dioscoreae, and above three tastes of Poria are ground into fine powder, sieve, all the other ten decoctings 2 times simply, each 30 minutes, concentrated, spraying was dry.Mix, granule processed, dry, make capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410363268.1A CN104116990A (en) | 2014-07-26 | 2014-07-26 | Medicinal composition for treating diabetes mellitus and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410363268.1A CN104116990A (en) | 2014-07-26 | 2014-07-26 | Medicinal composition for treating diabetes mellitus and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104116990A true CN104116990A (en) | 2014-10-29 |
Family
ID=51762770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410363268.1A Pending CN104116990A (en) | 2014-07-26 | 2014-07-26 | Medicinal composition for treating diabetes mellitus and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104116990A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104587337A (en) * | 2014-12-31 | 2015-05-06 | 李玉宾 | Traditional Chinese medicine composition for treating diabetes and preparation method of traditional Chinese medicine composition |
| CN105412647A (en) * | 2015-12-08 | 2016-03-23 | 鹿哲维 | Traditional Chinese medicinal composition for treating diabetics with syndrome of fire excess from yin deficiency |
| CN106474250A (en) * | 2016-10-31 | 2017-03-08 | 广西万德药业有限公司 | A kind of Chinese medicine composition containing southern stilbene and preparation method thereof |
| CN106619984A (en) * | 2016-10-31 | 2017-05-10 | 广西万德药业有限公司 | Guava leaf-containing traditional Chinese medicine composition and preparation method thereof |
| CN106668428A (en) * | 2016-10-31 | 2017-05-17 | 广西万德药业有限公司 | Blood sugar reducing traditional Chinese medicine composition and preparation method thereof |
| US20210393730A1 (en) * | 2020-06-17 | 2021-12-23 | Lytone Enterprise, Inc. | Herbal composition for reducing uric acid and the use in reducing uric acid, body fat, and blood glucose thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1425421A (en) * | 2002-12-31 | 2003-06-25 | 张晴龙 | Medicine for curing diabetes and its preparing method |
| CN1686303A (en) * | 2005-03-22 | 2005-10-26 | 李辉 | Chinese medicinal preparation for treating diabetes and its preparation method |
| CN102225149A (en) * | 2007-07-27 | 2011-10-26 | 北京亚东生物制药有限公司 | Traditional Chinese medicine compound for treating diabetes and preparation method thereof |
| JP2014034562A (en) * | 2012-08-10 | 2014-02-24 | Lotte Kenko Sangyo:Kk | Adiponectin production promoting agent |
-
2014
- 2014-07-26 CN CN201410363268.1A patent/CN104116990A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1425421A (en) * | 2002-12-31 | 2003-06-25 | 张晴龙 | Medicine for curing diabetes and its preparing method |
| CN1686303A (en) * | 2005-03-22 | 2005-10-26 | 李辉 | Chinese medicinal preparation for treating diabetes and its preparation method |
| CN102225149A (en) * | 2007-07-27 | 2011-10-26 | 北京亚东生物制药有限公司 | Traditional Chinese medicine compound for treating diabetes and preparation method thereof |
| JP2014034562A (en) * | 2012-08-10 | 2014-02-24 | Lotte Kenko Sangyo:Kk | Adiponectin production promoting agent |
Non-Patent Citations (5)
| Title |
|---|
| 王启才: "《药膳食疗治百病》", 31 January 2014, 西安交通大学出版社 * |
| 薛士明: "消渴汤合消渴丸治疗2型糖尿病30例", 《安徽中医学院学报》 * |
| 陈民: "王文彦教授对消渴病的独到认识", 《中医函授通讯》 * |
| 高新彦等: "《糖尿病中医诊疗经验集》", 30 March 2012, 西安交通大学出版社 * |
| 高纪武等: "《高纪武医案》", 31 October 2012, 第四军医大学出版社 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104587337A (en) * | 2014-12-31 | 2015-05-06 | 李玉宾 | Traditional Chinese medicine composition for treating diabetes and preparation method of traditional Chinese medicine composition |
| CN105412647A (en) * | 2015-12-08 | 2016-03-23 | 鹿哲维 | Traditional Chinese medicinal composition for treating diabetics with syndrome of fire excess from yin deficiency |
| CN106474250A (en) * | 2016-10-31 | 2017-03-08 | 广西万德药业有限公司 | A kind of Chinese medicine composition containing southern stilbene and preparation method thereof |
| CN106619984A (en) * | 2016-10-31 | 2017-05-10 | 广西万德药业有限公司 | Guava leaf-containing traditional Chinese medicine composition and preparation method thereof |
| CN106668428A (en) * | 2016-10-31 | 2017-05-17 | 广西万德药业有限公司 | Blood sugar reducing traditional Chinese medicine composition and preparation method thereof |
| US20210393730A1 (en) * | 2020-06-17 | 2021-12-23 | Lytone Enterprise, Inc. | Herbal composition for reducing uric acid and the use in reducing uric acid, body fat, and blood glucose thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104116990A (en) | Medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN103285231A (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN103191332A (en) | Composition and health-care product with stomach-invigorating and digestion-promoting functions | |
| CN101972338A (en) | Chinese medicinal preparation for treating infantile upper respiratory tract infection and preparation method thereof | |
| CN102343023A (en) | Medicinal composition and preparation method and application thereof | |
| CN101856405B (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN111388620A (en) | Composition for tonifying qi, strengthening spleen, promoting circulation and helping digestion and preparation method and application thereof | |
| CN101732698B (en) | Traditional Chinese medicine preparation with effect of lowering blood sugar, preparation method and application thereof | |
| CN103845607A (en) | Compound traditional Chinese medicinal preparation for preventing and treating diabetes mellitus and preparation method thereof | |
| CN106420955A (en) | Traditional Chinese medicine composition with blood glucose reduction assistance effect, preparation method and product of traditional Chinese medicine composition | |
| CN101279034B (en) | Combined Chinese medicament for curing diabetic with combined internal and external therapies and preparation thereof | |
| CN107961272B (en) | Traditional Chinese medicine composition for treating chronic kidney diseases | |
| CN106075056A (en) | A kind of Ganoderma lucidum and preparation method improving immunity and improving gastrointestinal function | |
| CN110772552A (en) | Ginseng tablet capable of improving immunity and preparation method thereof | |
| CN101491668B (en) | Composition with blood-sugar reducing function and preparation method thereof | |
| CN103251827A (en) | Traditional Chinese medicine composition for treating diabetes mellitus and preparation method thereof | |
| CN100998782A (en) | Traditional Chinese medicine oral liquid for treating gastrointestinal disease and its preparing method | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN104983759A (en) | Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof | |
| CN105055851A (en) | Chinese medicinal composition for treatment of diabetes, preparation and application thereof | |
| CN103263580A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN110585329A (en) | Pharmaceutical composition with blood sugar reducing effect and preparation method and application thereof | |
| CN104587175A (en) | Formula of traditional Chinese medicine for treating diabetes mellitus | |
| CN103405574A (en) | Medicinal composition for treating hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141029 |
|
| RJ01 | Rejection of invention patent application after publication |